Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy

We compared the short-term outcomes between 3-monthly aflibercept and brolucizumab injections for treatment-naïve polypoidal choroidal vasculopathy (PCV). A total of 52 eyes were included. Patients received 3 monthly intravitreal aflibercept (<i>n</i> = 38) or intravitreal brolucizumab (...

Full description

Bibliographic Details
Main Authors: Yoshiko Fukuda, Yoichi Sakurada, Mio Matsubara, Yuka Hasebe, Atsushi Sugiyama, Wataru Kikushima, Kenji Kashiwagi
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Biomedicines
Subjects:
polypoidal choroidal vasculopathy
brolucizumab
aflibercept
intraocular inflammation
resolution of polypoidal lesion(s)
Online Access:https://www.mdpi.com/2227-9059/9/9/1164

Similar Items

Similar Items